Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
    ACCESS Newswire

    New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

    April 30, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.

    HEIDELBERG, GERMANY / ACCESSWIRE / April 30, 2024 / BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.

    Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.

    Dr. Semih Akincilar, the scientist leading this project, explains: “Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment.”

    The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. “With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology,” said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).

    About BioMed X

    BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

    Contact Information

    Flavia-Bianca Cristian
    Recruiting & Communications Manager
    fbc@bio.mx
    +49 6221 426 11 706

    SOURCE: BioMed X Institute

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026
    Latest News

    Guinea declares mpox outbreak over after 42 days without cases

    Health November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.